Tag: Cardiometabolic
-
Expanding the TPP: Advanced Considerations for Market Access Success
In our previous exploration of the Target Product Profile (TPP), we laid the groundwork for understanding its pivotal role in navigating the complex terrain of market access. But the TPP is not just a static document: it’s a living blueprint that must adapt to the evolving business landscape. In this follow-up post, we expand on… Read more
-
Understanding Drug Pricing Strategies with GLP-1 Agents
In the dynamic world of biopharma, understanding drug pricing strategies is more than just an academic exercise—it’s a crucial element of market success. Glucagon-like peptide 1 (GLP-1) agonists1 such as Novo Nordisk’s Ozempic, Novo Nordisk’s Wegovy, Eli Lilly’s Mounjaro, and Eli Lilly’s Zepbound offer a set of case studies that are helpful in illustrating common… Read more
-
5 Trends Shaping Biopharma Market Access in 2023
The biopharmaceutical landscape is in a state of continual evolution, driven by scientific advancements, regulatory shifts, and market dynamics. As we venture deeper into 2023, several notable trends are shaping the market access paradigm, warranting attention from stakeholders across the industry spectrum. From policy enactments like the Inflation Reduction Act to the burgeoning realm of… Read more